Shire/Noven Gain Additional Quota For Daytrana Active Ingredient
This article was originally published in The Pink Sheet Daily
Executive Summary
DEA approves quota to manufacture additional quantities of methylphenidate used in the transdermal attention deficit/hyperactivity disorder treatment in 2006.
You may also be interested in...
Shire/Noven Daytrana Patch To Carry Similar Warnings To Other ADHD Drugs, FDA Says
The transdermal methylphenidate patch is approved with one additional warning relating to skin reactions and possible sensitivity to oral methylphenidate products.
Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.
MADIT-CRT Data Support Expanded Cardiac Resynchronization Market
The results show that cardiac resynchronization defibrillators "slow the progression of heart failure in asymptomatic and mildly symptomatic patients," potentially expanding the market by $600 million.